Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Applied Molecular Transport Inc (AMTI)

Applied Molecular Transport Inc (AMTI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,837
  • Shares Outstanding, K 38,943
  • Annual Sales, $ 0 K
  • Annual Income, $ -100,290 K
  • 60-Month Beta 1.48
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.49
Trade AMTI with:

Options Overview Details

View History
  • Implied Volatility 736.90% ( +295.08%)
  • Historical Volatility 117.38%
  • IV Percentile 99%
  • IV Rank 88.07%
  • IV High 836.19% on 11/22/22
  • IV Low 3.80% on 01/11/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 110
  • Volume Avg (30-Day) 73
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,923
  • Open Int (30-Day) 878

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.66
  • Number of Estimates 2
  • High Estimate -0.65
  • Low Estimate -0.66
  • Prior Year -0.78
  • Growth Rate Est. (year over year) +15.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8100 +43.21%
on 11/22/22
1.3200 -12.12%
on 11/17/22
+0.2350 (+25.41%)
since 11/09/22
3-Month
0.8025 +44.55%
on 11/03/22
1.5300 -24.18%
on 09/13/22
-0.1800 (-13.43%)
since 09/09/22
52-Week
0.8025 +44.55%
on 11/03/22
15.2700 -92.40%
on 12/16/21
-13.5400 (-92.11%)
since 12/09/21

Most Recent Stories

More News
Applied Molecular Transport Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis Orphan indication with no FDA-approved productsCompany granted...

AMTI : 1.1600 (+5.45%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Molecular Transport Inc. - AMTI

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Applied Molecular Transport Inc. ("Applied Molecular" or the "Company") (NYSE:...

AMTI : 1.1600 (+5.45%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Molecular Transport Inc. - AMTI

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Applied Molecular Transport Inc. ("Applied Molecular" or the "Company") (NYSE:...

AMTI : 1.1600 (+5.45%)
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Applied Molecular Transport Inc. with Losses of $100,000 to Contact the Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Applied Molecular Transport Inc. (“Applied Molecular” or “the...

AMTI : 1.1600 (+5.45%)
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Applied Molecular Transport Inc. with Losses of $100,000 to Contact the Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Applied Molecular Transport Inc. (“Applied Molecular” or “the...

AMTI : 1.1600 (+5.45%)
Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

Live Conference Call and Webcast on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. ...

AMTI : 1.1600 (+5.45%)
10 Penny Stocks with > 1,000% Upside

Rising interest rates, sky-high inflation, and geopolitical concerns have dragged down the S&P 500 (SPX) and NASDAQ Composite (NDX) into bear market territory. While all this sounds rather doom and gloom,...

AMTI : 1.1600 (+5.45%)
ANGN : 0.8321 (+0.25%)
CKPT : 3.72 (+0.27%)
EFTR : 0.4208 (+7.90%)
FRLN : 0.5525 (-6.36%)
GLYC : 2.07 (-11.91%)
MGNX : 6.24 (+0.32%)
OCUP : 3.08 (unch)
PHAS : 0.0701 (-26.21%)
Applied Molecular Transport Provides Strategy Update

Company streamlines to prioritize resources on key proprietary clinical programs, including plans to advance AMT-101 into Phase 3 for chronic pouchitis ...

AMTI : 1.1600 (+5.45%)
Applied Molecular Transport Reports First Quarter 2022 Financial Results and Provides Corporate Update

Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis Independent Data Monitoring Committee (DMC) recommends advancing...

AMTI : 1.1600 (+5.45%)
Applied Molecular Transport to Present at BofA Securities 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical...

AMTI : 1.1600 (+5.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company. It design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic and other diseases. The company's lead product candidate consist AMT-101, which is in clinical stage....

See More

Key Turning Points

3rd Resistance Point 1.4067
2nd Resistance Point 1.3133
1st Resistance Point 1.2367
Last Price 1.1600
1st Support Level 1.0667
2nd Support Level 0.9733
3rd Support Level 0.8967

See More

52-Week High 15.2700
Fibonacci 61.8% 9.7434
Fibonacci 50% 8.0363
Fibonacci 38.2% 6.3291
Last Price 1.1600
52-Week Low 0.8025

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar